Stem Cell Therapy
Drugs in development to treat moderate to severe subacute and chronic atopic dermatitis
ADSTEM Inj. Overview
Our company is currently developing treatments for moderate to severe subacute and chronic atopic dermatitis, with Phase 1 clinical trials underway at Chungnam National University Hospital.
We are continuing research and development to obtain approval for adult stem cell therapy products through Phase 2 and Phase 3 clinical trials.
Our ADSTEM Inj. targets moderate to subacute and chronic atopic dermatitis.
Low Dose 1.0 x 108 cell / 10 ml / syringe
High Dose 3.0 x 108 cell / 10 ml / 3 syringes
One-time intravenous administration of autologous adipose-derived stem cells